Concepedia

Ricardo E. Dent‐Acosta

RE

6

Publications

780

Citations

6

H-Index

2011

Active since

Affiliations

Amgen (United States)(Current)

Baylor College of Medicine

McMaster University

Sanofi (United States)

University of California, San Francisco

Ricardo E. Dent‐Acosta is an author at Amgen (United States) specializing in pharmacotherapy, medicine, and cardiovascular disease.

ORCID

Top concepts

Publications per year

2011–2020

6

Publications

6

Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance

Steven E. Nissen, Erik S.G. Stroes, Ricardo E. Dent‐Acosta et al. · JAMA · 2016 · 502 citations · Full text

Bone remodeling in postmenopausal women who discontinued denosumab treatment: Off-treatment biopsy study

Jacques P. Brown, David W. Dempster, Beiying Ding et al. · Journal of Bone and Mineral Research · 2011 · 89 citations · Full text

A Randomized, Placebo-Controlled Study of Romosozumab for the Treatment of Hip Fractures

Emil H. Schemitsch, Theodore Miclau, Theofilos Karachalios et al. · Journal of Bone and Joint Surgery · 2020 · 82 citations · Full text

Romosozumab in Skeletally Mature Adults with a Fresh Unilateral Tibial Diaphyseal Fracture

Mohit Bhandari, Emil H. Schemitsch, Theofilos Karachalios et al. · Journal of Bone and Joint Surgery · 2020 · 48 citations

Comparison of <scp>PCSK9</scp> Inhibitor Evolocumab vs Ezetimibe in Statin‐Intolerant Patients: Design of the Goal Achievement After Utilizing an Anti‐<scp>PCSK9</scp> Antibody in Statin‐Intolerant Subjects 3 (<scp>GAUSS</scp>‐3) Trial

Steven E. Nissen, Ricardo E. Dent‐Acosta, Robert S. Rosenson et al. · Clinical Cardiology · 2016 · 43 citations · Full text

, , +15

Rows per page

1–5 of 6